Advertisement

Topics

These highlights do not include all the information needed to use DARZALEXsafely and effectively. See full prescribing information for DARZALEX. DARZALEX (daratumumab) injection, for intravenous use Initial U.S. Approval – 2015 | DARZALEX [Janssen Biotech, Inc.] | BioPortfolio

12:40 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

DARZALEX is indicated:

Newly Diagnosed Multiple Myeloma

Dosing Schedule for DARZALEX in Combination with Bortezomib, Melphalan and Prednisone (6-week cycle regimen) for Patients Ineligible for Autologous Stem Cell Transplant

The recommended dose of DARZALEX is 16 mg/kg actual body weight administered as an intravenous infusion according to the following dosing schedule in Table 1.

For dosing instructions of combination agents administered with DARZALEX see Clinical Studies (14.1).

Table 1: DARZALEX dosing schedule in combination with bortezomib, melphalan and prednisone ([VMP], 6-week cycle dosing regimen)
Weeks Schedule
Weeks 1 to 6 weekly (total of 6 doses)
Weeks 7 to 54First dose of the every-3-week dosing schedule is given at Week 7 every three weeks (total of 16 doses)
Week 55 onwards until disease progressionFirst dose of the every-4-week dosing schedule is given at Week 55 every four weeks

Relapsed/Refractory Multiple Myeloma

Monotherapy and Combination Therapy with Lenalidomide or Pomalidomide and Low-Dose Dexamethasone (4-week cycle regimens)

The recommended dose of DARZALEX is 16 mg/kg actual body weight administered as an intravenous infusion according to the following dosing schedule in Table 2:

For dosing instructions of combination agents administered with DARZALEX, see Clinical Studies (14.2) and manufacturer's prescribing information.

Table 2: DARZALEX dosing schedule for monotherapy and in combination with lenalidomide or pomalidomide (4-week cycle dosing regimens)
Weeks Schedule
Weeks 1 to 8 weekly (total of 8 doses)
Weeks 9 to 24First dose of the every-2-week dosing schedule is given at Week 9 every two weeks (total of 8 doses)
Week 25 onwards until disease progressionFirst dose of the every-4-week dosing schedule is given at Week 25 every four weeks

Combination Therapy with Bortezomib and Dexamethasone (3-week cycle regimen)

The recommended dose of DARZALEX is 16 mg/kg actual body weight administered as an intravenous infusion according to the following dosing schedule in Table 3:

For dosing instructions of combination agents administered with DARZALEX see Clinical Studies (14.2) and manufacturer's prescribing information.

Table 3: DARZALEX dosing schedule with bortezomib (3-week cycle dosing regimen)
Weeks Schedule
Weeks 1 to 9 weekly (total of 9 doses)
Weeks 10 to 24First dose of the every-3-week dosing schedule is given at Week 10 every three weeks (total of 5 doses)
Week 25 onwards until disease progressionFirst dose of the every-4-week dosing schedule is given at Week 25 every four weeks

Missed DARZALEX Doses

If a planned dose of DARZALEX is missed, administer the dose as soon as possible and adjust the dosing schedule accordingly, maintaining the treatment interval.

Infusion Rates and Management of Infusion Reactions

Administer DARZALEX infusion intravenously at the infusion rate described below in Table 4. Consider incremental escalation of the infusion rate only in the absence of infusion reactions.

For infusion reactions of any grade/severity, immediately interrupt the DARZALEX infusion and manage symptoms. Management of infusion reactions may further require reduction in the rate of infusion, or treatment discontinuation of DARZALEX as outlined below [see Warnings and Precautions (5.1)].

Table 4: Infusion rates for DARZALEX administration
Dilution volume Initial rate (first hour) Rate incrementConsider incremental escalation of the infusion rate only in the absence of infusion reactions. Maximum rate
First infusion 1000 mL 50 mL/hour 50 mL/hour every hour 200 mL/hour
Second infusion Use a dilution volume of 500 mL only if there were no infusion reactions during the first 3 hours of the first infusion. Otherwise, continue to use a dilution volume of 1000 mL and instructions for the first infusion. 500 mL 50 mL/hour 50 mL/hour every hour 200 mL/hour
Subsequent infusions Use a modified initial rate for subsequent infusions (i.e. third infusion onwards) only if there were no infusion reactions during a final infusion rate of ≥100 mL/hr in the first two infusions. Otherwise, continue to use instructions for the second infusion. 500 mL 100 mL/hour 50 mL/hour every hour 200 mL/hour

Pre-infusion Medication

Administer the following pre-infusion medications to reduce the risk of infusion reactions to all patients 1–3 hours prior to every infusion of DARZALEX:

Post-infusion Medication

Administer post-infusion medication to reduce the risk of delayed infusion reactions to all patients as follows:

Monotherapy:

Administer oral corticosteroid (20 mg methylprednisolone or equivalent dose of an intermediate-acting or long-acting corticosteroid in accordance with local standards) on each of the 2 days following all DARZALEX infusions (beginning the day after the infusion).

Combination therapy:

Consider administering low-dose oral methylprednisolone (≤ 20 mg) or equivalent, the day after the DARZALEX infusion.

However, if a background regimen-specific corticosteroid (e.g. dexamethasone, prednisone) is administered the day after the DARZALEX infusion, additional post-infusion medications may not be needed [see Clinical Studies (14)].

In addition, for any patients with a history of chronic obstructive pulmonary disease, consider prescribing post-infusion medications such as short and long-acting bronchodilators, and inhaled corticosteroids. Following the first four infusions, if the patient experiences no major infusion reactions, these additional inhaled post-infusion medications may be discontinued.

Prophylaxis for Herpes Zoster Reactivation

Initiate antiviral prophylaxis to prevent herpes zoster reactivation within 1 week after starting DARZALEX and continue for 3 months following treatment [see Adverse Reactions (6.1)].

No dose reductions of DARZALEX are recommended. Dose delay may be required to allow recovery of blood cell counts in the event of hematological toxicity [see Warnings and Precautions (5.3, 5.4)]. For information concerning drugs given in combination with DARZALEX, see manufacturer's prescribing information.

DARZALEX is for single use only.

Prepare the solution for infusion using aseptic technique as follows:

DARZALEX is a colorless to pale yellow, preservative-free solution available as:

Injection:

DARZALEX is contraindicated in patients with a history of severe hypersensitivity (e.g. anaphylactic reactions) to daratumumab or any of the components of the formulation [see Warnings and Precautions (5.1) and Adverse Reactions (6.3)].

DARZALEX can cause severe and/or serious infusion reactions including anaphylactic reactions. In clinical trials, approximately half of all patients experienced an infusion reaction. Most infusion reactions occurred during the first infusion and were Grade 1–2 [see Adverse Reactions (6.1)].

Infusion reactions can also occur with subsequent infusions. Nearly all reactions occurred during infusion or within 4 hours of completing DARZALEX. Prior to the introduction of post-infusion medication in clinical trials, infusion reactions occurred up to 48 hours after infusion.

Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema. Signs and symptoms may include respiratory symptoms, such as nasal congestion, cough, throat irritation, as well as chills, vomiting and nausea. Less common symptoms were wheezing, allergic rhinitis, pyrexia, chest discomfort, pruritus, and hypotension [see Adverse Reactions (6.1)].

Pre-medicate patients with antihistamines, antipyretics and corticosteroids. Frequently monitor patients during the entire infusion. Interrupt DARZALEX infusion for reactions of any severity and institute medical management as needed. Permanently discontinue DARZALEX therapy if an anaphylactic reaction or life-threatening (Grade 4) reaction occurs and institute appropriate emergency care. For patients with Grade 1, 2, or 3 reactions, reduce the infusion rate when re-starting the infusion [see Dosage and Administration (2.1)].

To reduce the risk of delayed infusion reactions, administer oral corticosteroids to all patients following DARZALEX infusions [see Dosage and Administration (2.2)]. Patients with a history of chronic obstructive pulmonary disease may require additional post-infusion medications to manage respiratory complications. Consider prescribing short- and long-acting bronchodilators and inhaled corticosteroids for patients with chronic obstructive pulmonary disease.

Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (Indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab infusion. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum [see References (15)]. The determination of a patient's ABO and Rh blood type are not impacted [see Drug Interactions (7.1)].

Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX. Type and screen patients prior to starting DARZALEX.

DARZALEX may increase neutropenia induced by background therapy [see Adverse Reactions (6.1)].

Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. DARZALEX dose delay may be required to allow recovery of neutrophils. No dose reduction of DARZALEX is recommended. Consider supportive care with growth factors.

DARZALEX may increase thrombocytopenia induced by background therapy [see Adverse Reactions (6.1)].

Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. DARZALEX dose delay may be required to allow recovery of platelets. No dose reduction of DARZALEX is recommended. Consider supportive care with transfusions.

Daratumumab is a human IgG kappa monoclonal antibody that can be detected on both, the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein [see Drug Interactions (7.1)]. This interference can impact the determination of complete response and of disease progression in some patients with IgG kappa myeloma protein.

The following serious adverse reactions are also described elsewhere in the labeling:

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety data described below reflects exposure to DARZALEX (16 mg/kg) in 1166 patients with multiple myeloma including 872 patients from three Phase 3 active-controlled trials who received DARZALEX in combination with either lenalidomide and dexamethasone (DRd, n=283; POLLUX), bortezomib and dexamethasone (DVd, n=243; CASTOR) or bortezomib, melphalan and prednisone (D-VMP, n=346; ALCYONE), and five open-label, clinical trials in which patients received DARZALEX either in combination with pomalidomide and dexamethasone (DPd, n=103; EQUULEUS), in combination with lenalidomide and dexamethasone (n=35), or as monotherapy (n=156).

Newly Diagnosed Multiple Myeloma

Combination Treatment with Bortezomib, Melphalan and Prednisone

Adverse reactions described in Table 5 reflect exposure to DARZALEX (D-VMP arm) for a median treatment duration of 14.7 months (range: 0 to 25.8 months) and median treatment duration of 12 months (range: 0.1 to 14.9 months) for the VMP group in ALCYONE. The most frequent adverse reactions (≥20% with at least 5% greater frequency in the D-VMP arm) were infusion reactions, upper respiratory tract infection and edema peripheral. Serious adverse reactions with at least a 2% greater incidence in the D-VMP arm compared to the VMP arm were pneumonia (D-VMP 11% vs VMP 4%), upper respiratory tract infection (D-VMP 5% vs VMP 1%), and pulmonary edema (D-VMP 2% vs VMP 0%).

Laboratory abnormalities worsening during treatment from baseline listed in Table 6.

Table 5: Adverse reactions reported in ≥10% of patients and with at least a 5% greater frequency in the D-VMP arm in ALCYONE
Body System
Adverse Reaction
D-VMP (N=346) VMP (N=354)
Any Grade
(%)
Grade 3
(%)
Grade 4
(%)
Any Grade
(%)
Grade 3
(%)
Grade 4
(%)
Key: D=daratumumab, VMP=bortezomib-melphalan-prednisone
Infusion reactionsInfusion reaction includes terms determined by investigators to be related to infusion, see description of Infusion Reactions below. 28 4 1 0 0 0
General disorders and administration site conditions
  Edema peripheraledema peripheral, generalized edema, peripheral swelling 21 1 < 1 14 1 0
Infections and infestations
  Upper respiratory tract infectionupper respiratory tract infection, bronchitis, bronchitis bacterial, epiglottitis, laryngitis, laryngitis bacterial, metapneumovirus infection, nasopharyngitis, oropharyngeal candidiasis, pharyngitis, pharyngitis streptococcal, respiratory syncytial virus infection, respiratory tract infection, respiratory tract infection viral, rhinitis, sinusitis, tonsillitis, tracheitis, tracheobronchitis, viral pharyngitis, viral rhinitis, viral upper respiratory tract infection. 48 5 0 28 3 0
  Pneumoniapneumonia, lung infection, pneumonia aspiration, pneumonia bacterial, pneumonia pneumococcal, pneumonia streptococcal, pneumonia viral, and pulmonary sepsis 16 12 < 1 6 5 < 1
Respiratory, thoracic and mediastinal disorders
  Coughcough, productive cough 16 < 1 0 8 < 1 0
  Dyspneadyspnea, dyspnea exertional 13 2 1 5 1 0
Vascular disorders
  Hypertensionhypertension, blood pressure increased 10 4 < 1 3 2 0
Table 6: Treatment-emergent hematology laboratory abnormalities in ALCYONE
D-VMP (N=346) % VMP (N=354) %
Any Grade Grade 3 Grade 4 Any Grade Grade 3 Grade 4
Key: D=daratumumab, VMP=bortezomib-melphalan-prednisone
Anemia 47 18 0 50 21 0
Thrombocytopenia 88 27 11 88 26 16
Neutropenia 86 34 10 87 32 11
Lymphopenia 85 46 12 83 44 9

Relapsed/Refractory Multiple Myeloma

Combination Treatment with Lenalidomide

Adverse reactions described in Table 7 reflect exposure to DARZALEX (DRd arm) for a median treatment duration of 13.1 months (range: 0 to 20.7 months) and median treatment duration of 12.3 months (range: 0.2 to 20.1 months) for the lenalidomide group (Rd) in POLLUX. The most frequent adverse reactions (≥20%) were infusion reactions, diarrhea, nausea, fatigue, pyrexia, upper respiratory tract infection, muscle spasms, cough and dyspnea. The overall incidence of serious adverse reactions was 49% for the DRd group compared with 42% for the Rd group. Serious adverse reactions with at least a 2% greater incidence in the DRd arm compared to the Rd arm were pneumonia (DRd 12% vs Rd 10%), upper respiratory tract infection (DRd 7% vs Rd 4%), influenza and pyrexia (DRd 3% vs Rd 1% for each).

Adverse reactions resulted in discontinuations for 7% (n=19) of patients in the DRd arm versus 8% (n=22) in the Rd arm.

Laboratory abnormalities worsening during treatment from baseline listed in Table 8.

Table 7: Adverse reactions reported in ≥ 10% of patients and with at least a 5% greater frequency in the DRd arm in POLLUX
Adverse Reaction DRd (N=283) % Rd (N=281) %
Any Grade Grade 3 Grade 4 Any Grade Grade 3 Grade 4
Key: D=daratumumab, Rd=lenalidomide-dexamethasone.
Infusion reactionsInfusion reaction includes terms determined by investigators to be related to infusion, see description of Infusion Reactions below. 48 5 0 0 0 0
Gastrointestinal disorders
  Diarrhea 43 5 0 25 3 0
  Nausea 24 1 0 14 0 0
  Vomiting 17 1 0 5 1 0
General disorders and administration site conditions
  Fatigue 35 6 < 1 28 2 0
  Pyrexia 20 2 0 11 1 0
Infections and infestations
  Upper respiratory tract infectionupper respiratory tract infection, bronchitis, sinusitis, respiratory tract infection viral, rhinitis, pharyngitis, respiratory tract infection, metapneumovirus infection, tracheobronchitis, viral upper respiratory tract infection, laryngitis, respiratory syncytial virus infection, staphylococcal pharyngitis, tonsillitis, viral pharyngitis, acute sinusitis, nasopharyngitis, bronchiolitis, bronchitis viral, pharyngitis streptococcal, tracheitis, upper respiratory tract infection bacterial, bronchitis bacterial, epiglottitis, laryngitis viral, oropharyngeal candidiasis, respiratory moniliasis, viral rhinitis, acute tonsillitis, rhinovirus infection 65 6 < 1 51 4 0
Musculoskeletal and connective tissue disorders
  Muscle spasms 26 1 0 19 2 0
Nervous system disorders
  Headache 13 0 0 7 0 0
Respiratory, thoracic and mediastinal disorders
  Coughcough, productive cough, allergic cough 30 0 0 15 0 0
  Dyspneadyspnea, dyspnea exertional 21 3 < 1 12 1 0
Table 8: Treatment-emergent hematology laboratory abnormalities in POLLUX
DRd (N=283) % Rd (N=281) %
Any Grade Grade 3 Grade 4 Any Grades Grade 3 Grade 4
Key: D=Daratumumab, Rd=lenalidomide-dexamethasone.
Anemia 52 13 0 57 19 0
Thrombocytopenia 73 7 6 67 10 5
Neutropenia 92 36 17 87 32 8
Lymphopenia 95 42 10 87 32 6

Combination Treatment with Bortezomib

Adverse reactions described in Table 9 reflect exposure to DARZALEX (DVd arm) for a median treatment duration of 6.5 months (range: 0 to 14.8 months) and median treatment duration of 5.2 months (range: 0.2 to 8.0 months) for the bortezomib group (Vd) in CASTOR. The most frequent adverse reactions (>20%) were infusion reactions, diarrhea, peripheral edema, upper respiratory tract infection, peripheral sensory neuropathy, cough and dyspnea. The overall incidence of serious adverse reactions was 42% for the DVd group compared with 34% for the Vd group. Serious adverse reactions with at least a 2% greater incidence in the DVd arm compared to the Vd arm were upper respiratory tract infection (DVd 5% vs Vd 2%), diarrhea and atrial fibrillation (DVd 2% vs Vd 0% for each).

Adverse reactions resulted in discontinuations for 7% (n=18) of patients in the DVd arm versus 9% (n=22) in the Vd arm.

Laboratory abnormalities worsening during treatment are listed in Table 10.

Table 9: Adverse reactions reported in ≥ 10% of patients and with at least a 5% greater frequency in the DVd arm CASTOR
Adverse Reaction DVd (N=243) % Vd (N=237) %
Any Grade Grade 3 Grade 4 Any Grade Grade 3 Grade 4
Key: D=daratumumab, Vd=bortezomib-dexamethasone.
Infusion reactionsInfusion reaction includes terms determined by investigators to be related to infusion, see description of Infusion Reactions below. 45 9 0 0 0 0
Gastrointestinal disorders
  Diarrhea 32 3 < 1 22 1 0
  Vomiting 11 0 0 4 0 0
General disorders and administration site conditions
  Edema peripheraledema peripheral, edema, generalized edema, peripheral swelling 22 1 0 13 0 0
  Pyrexia 16 1 0 11 1 0
Infections and infestations
  Upper respiratory tract infectionupper respiratory tract infection, bronchitis, sinusitis, respiratory tract infection viral, rhinitis, pharyngitis, respiratory tract infection, metapneumovirus infection, tracheobronchitis, viral upper respiratory tract infection, laryngitis, respiratory syncytial virus infection, staphylococcal pharyngitis, tonsillitis, viral pharyngitis, acute sinusitis, nasopharyngitis, bronchiolitis, bronchitis viral, pharyngitis streptococcal, tracheitis, upper respiratory tract infection bacterial, bronchitis bacterial, epiglottitis, laryngitis viral, oropharyngeal candidiasis, respiratory moniliasis, viral rhinitis, acute tonsillitis, rhinovirus infection 44 6 0 30 3 < 1
Nervous system disorders
  Peripheral sensory neuropathy 47 5 0 38 6 < 1
Respiratory, thoracic and mediastinal disorders
  Coughcough, productive cough, allergic cough 27 0 0 14 0 0
  Dyspneadyspnea, dyspnea exertional 21 4 0 11 1 0
Table 10: Treatment-emergent hematology laboratory abnormalities in CASTOR
DVd (N=243) % Vd (N=237) %
Any Grade Grade 3 Grade 4 Any Grade Grade 3 Grade 4
Key: D=Daratumumab, Vd=bortezomib-dexamethasone.
Anemia 48 13 0 56 14 0
Thrombocytopenia 90 28 19 85 22 13
Neutropenia 58 12 3 40 5 < 1
Lymphopenia 89 41 7 81 24 3

Combination Treatment with Pomalidomide

Adverse reactions described in Table 11 reflect exposure to DARZALEX, pomalidomide and dexamethasone (DPd) for a median treatment duration of 6 months (range: 0.03 to 16.9 months) in EQUULEUS. The most frequent adverse reactions (>20%) were infusion reactions, diarrhea, constipation, nausea, vomiting, fatigue, pyrexia, upper respiratory tract infection, muscle spasms, back pain, arthralgia, dizziness, insomnia, cough and dyspnea. The overall incidence of serious adverse reactions was 49%. Serious adverse reactions reported in ≥5% patients included pneumonia (7%). Adverse reactions resulted in discontinuations for 13% of patients.

Laboratory abnormalities worsening during treatment are listed in Table 12.

Table 11: Adverse reactions with incidence ≥10% reported in EQUULEUS
Body System DPd (N=103)
  Adverse Reaction Any Grade (%) Grade 3 (%) Grade 4 (%)
Key: D=Daratumumab, Pd=pomalidomide-dexamethasone.
  Infusion reactionsInfusion reaction includes terms determined by investigators to be related to infusion, see description of Infusion Reactions below. 50 4 0
Gastrointestinal disorders
  Diarrhea 38 3 0
  Constipation 33 0 0
  Nausea 30 0 0
  Vomiting 21 2 0
General disorders and administration site conditions
  Fatigue 50 10 0
  Pyrexia 25 1 0
  Chills 20 0 0
  Edema peripheraledema, edema peripheral, peripheral swelling. 17 4 0
  Asthenia 15 0 0
  Non-cardiac chest pain 15 0 0
  Pain 11 0 0
Infections and infestations
  Upper respiratory tract infectionacute tonsillitis, bronchitis, laryngitis, nasopharyngitis, pharyngitis, respiratory syncytial virus infection, rhinitis, sinusitis, tonsillitis, upper respiratory tract infection 50 4 1
  Pneumonialung infection, pneumonia, pneumonia aspiration 15 8 2
Metabolism and nutrition disorders
  Hypokalemia 16 3 0
  Hyperglycemia 13 5 1
  Decreased appetite 11 0 0
Musculoskeletal and connective tissue disorders
  Muscle spasms 26 1 0
  Back pain 25 6 0
  Arthralgia 22 2 0
  Pain in extremity 15 0 0
  Bone pain 13 4 0
  Musculoskeletal chest pain 13 2 0
Nervous system disorders
  Dizziness 21 2 0
  Tremor 19 3 0
  Headache 17 0 0
Psychiatric disorders
  Insomnia 23 2 0
  Anxiety 13 0 0
Respiratory, thoracic and mediastinal disorders
  Coughcough, productive cough, allergic cough 43 1 0
  Dyspneadyspnea, dyspnea exertional 33 6 1
  Nasal congestion 16 0 0
Table 12: Treatment-emergent hematology laboratory abnormalities in EQUULEUS
DPd (N=103) %
Any Grade Grade 3 Grade 4
Key: D=Daratumumab, Pd=pomalidomide-dexamethasone.
Anemia 57 30 0
Thrombocytopenia 75 10 10
Neutropenia 95 36 46
Lymphopenia 94 45 26

Monotherapy

The safety data reflect exposure to DARZALEX in 156 adult patients with relapsed and refractory multiple myeloma treated with DARZALEX at 16 mg/kg in three open-label, clinical trials. The median duration of exposure was 3.3 months (range: 0.03 to 20.04 months). Serious adverse reactions were reported in 51 (33%) patients. The most frequent serious adverse reactions were pneumonia (6%), general physical health deterioration (3%), and pyrexia (3%).

Adverse reactions resulted in treatment delay for 24 (15%) patients, most frequently for infections. Adverse reactions resulted in discontinuations for 6 (4%) patients.

Adverse reactions occurring in at least 10% of patients are presented in Table 13. Table 14 describes Grade 3–4 laboratory abnormalities reported at a rate of ≥10%.

Table 13: Adverse reactions with incidence ≥10% in patients with multiple myeloma treated with DARZALEX 16 mg/kg
DARZALEX 16 mg/kg
N=156
Incidence (%)
  Adverse Reaction Any Grade Grade 3 Grade 4
  Infusion reactionInfusion reaction includes terms determined by investigators to be related to infusion, see below. 48 3 0
General disorders and administration site conditions
  Fatigue 39 2 0
  Pyrexia 21 1 0
  Chills 10 0 0
Respiratory, thoracic and mediastinal disorders
  Cough 21 0 0
  Nasal congestion 17 0 0
  Dyspnea 15 1 0
Musculoskeletal and connective tissue disorders
  Back pain 23 2 0
  Arthralgia 17 0 0
  Pain in extremity 15 1 0
  Musculoskeletal chest pain 12 1 0
Infections and infestations
  Upper respiratory tract infection 20 1 0
  Nasopharyngitis 15 0 0
  PneumoniaPneumonia also includes the terms streptococcal pneumonia and lobar pneumonia. 11 6 0
Gastrointestinal disorders
  Nausea 27 0 0
  Diarrhea 16 1 0
  Constipation 15 0 0
  Vomiting 14 0 0
Metabolism and nutrition disorders
  Decreased appetite 15 1 0
Nervous system disorders
  Headache 12 1 0
Vascular disorders
  Hypertension 10 5 0
Table 14: Treatment emergent Grade 3–4 laboratory abnormalities (≥10%)
Daratumumab 16 mg/kg (N=156)
Any Grade (%) Grade 3 (%) Grade 4 (%)
Anemia 45 19 0
Thrombocytopenia 48 10 8
Neutropenia 60 17 3
Lymphopenia 72 30 10

Infusion Reactions

In clinical trials (monotherapy and combination treatments; N=1166) the incidence of any grade infusion reactions was 40% with the first infusion of DARZALEX, 2% with the second infusion, and 4% with subsequent infusions. Less than 1% of patients had a Grade 3 infusion reaction with second or subsequent infusions. Grade 4 infusion reactions were reported in 2/1166 (0.2%) of patients.

The median time to onset of a reaction was 1.4 hours (range: 0 to 72.8 hours). The incidence of infusion modification due to reactions was 37%. Median durations of infusion for the 1, 2and subsequent infusions were 7.0, 4.3, and 3.4 hours respectively.

Severe infusion reactions included bronchospasm, dyspnea, laryngeal edema, pulmonary edema, hypoxia, and hypertension. Other adverse infusion reactions included nasal congestion, cough, chills, throat irritation, vomiting and nausea.

Herpes Zoster Virus Reactivation

Prophylaxis for Herpes Zoster Virus reactivation was recommended for patients in some clinical trials of DARZALEX. In monotherapy studies, herpes zoster was reported in 3% of patients. In the combination therapy studies, herpes zoster was reported in 2–5% of patients receiving DARZALEX.

Infections

In patients receiving DARZALEX combination therapy, Grade 3 or 4 infections were reported with DARZALEX combinations and background therapies (DVd: 21%, Vd: 19%; DRd: 28%, Rd: 23%; D-VMP:23%, VMP:15%; DPd: 28%). Pneumonia was the most commonly reported severe (Grade 3 or 4) infection across studies. Discontinuations from treatment were reported in 3% versus 2% of patients in the DRd and Rd groups respectively, 4% versus 3% of patients in the DVd and Vd groups respectively, 1% each in the D-VMP and VMP groups respectively, and in 5% of patients receiving DPd. Fatal infections were generally balanced between the DARZALEX containing regimens and active control arms (<2%) in the controlled studies and were primarily due to pneumonia and sepsis.

As with all therapeutic proteins, there is the potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to daratumumab in the studies described below with the incidence of antibodies in other studies or to other products may be misleading. In clinical trials of patients with multiple myeloma treated with DARZALEX as monotherapy or as combination therapies, none of the 111 evaluable monotherapy patients, and 2 of the 411 combination therapy patients, tested positive for anti-daratumumab antibodies. One patient administered DARZALEX as combination therapy, developed transient neutralizing antibodies against daratumumab. However, this assay has limitations in detecting anti-daratumumab antibodies in the presence of high concentrations of daratumumab; therefore, the incidence of antibody development might not have been reliably determined.

The following adverse reactions have been identified during post-approval use of DARZALEX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune System disorders: Anaphylactic reaction

Interference with Indirect Antiglobulin Tests (Indirect Coombs Test)

Daratumumab binds to CD38 on RBCs and interferes with compatibility testing, including antibody screening and cross matching. Daratumumab interference mitigation methods include treating reagent RBCs with dithiothreitol (DTT) to disrupt daratumumab binding [see References (15)] or genotyping. Since the Kell blood group system is also sensitive to DTT treatment, K-negative units should be supplied after ruling out or identifying alloantibodies using DTT-treated RBCs.

If an emergency transfusion is required, non-cross-matched ABO/RhD-compatible RBCs can be given per local blood bank practices.

Interference with Serum Protein Electrophoresis and Immunofixation Tests

Daratumumab may be detected on serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for monitoring disease monoclonal immunoglobulins (M protein). This can lead to false positive SPE and IFE assay results for patients with IgG kappa myeloma protein impacting initial assessment of complete responses by International Myeloma Working Group (IMWG) criteria. In patients with persistent very good partial response, where daratumumab interference is suspected, consider using a FDA-approved daratumumab-specific IFE assay to distinguish daratumumab from any remaining endogenous M protein in the patient's serum, to facilitate determination of a complete response.

Risk Summary

There are no human data to inform a risk with use of DARZALEX during pregnancy. Animal studies have not been conducted. However, there are clinical considerations [see Clinical Considerations]. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.

Clinical Considerations

Fetal/Neonatal Adverse Reactions

Immunoglobulin G1 (IgG1) monoclonal antibodies are transferred across the placenta. Based on its mechanism of action, DARZALEX may cause fetal myeloid or lymphoid-cell depletion and decreased bone density. Defer administering live vaccines to neonates and infants exposed to DARZALEX in utero until a hematology evaluation is completed.

Data

Animal Data

Mice that were genetically modified to eliminate all CD38 expression (CD38 knockout mice) had reduced bone density at birth that recovered by 5 months of age. In cynomolgus monkeys exposed during pregnancy to other monoclonal antibodies that affect leukocyte populations, infant monkeys had a reversible reduction in leukocytes.

Risk Summary

There is no information regarding the presence of daratumumab in human milk, the effects on the breastfed child, or the effects on milk production. Human IgG is known to be present in human milk. Published data suggest that antibodies in breast milk do not enter the neonatal and infant circulations in substantial amounts.

The developmental and health benefits of breast-feeding should be considered along with the mother's clinical need for DARZALEX and any potential adverse effects on the breast-fed child from DARZALEX or from the underlying maternal condition.

Contraception

To avoid exposure to the fetus, women of reproductive potential should use effective contraception during treatment and for 3 months after cessation of DARZALEX treatment.

Safety and effectiveness of DARZALEX in pediatric patients have not been established.

Of the 1166 patients that received DARZALEX at the recommended dose, 46% were 65 to 75 years of age, and 15% were 75 years of age or older. No overall differences in safety or effectiveness were observed between these patients and younger patients [see Clinical Studies (14)].

Daratumumab is an immunoglobulin G1 kappa (IgG1κ) human monoclonal antibody against CD38 antigen, produced in a mammalian cell line (Chinese Hamster Ovary [CHO]) using recombinant DNA technology. The molecular weight of daratumumab is approximately 148 kDa.

DARZALEX is supplied as a colorless to pale yellow preservative-free solution for intravenous infusion in single-dose vials. The pH is 5.5. DARZALEX must be diluted with 0.9% Sodium Chloride Injection, USP [see Dosage and Administration (2.4)].

Each DARZALEX single-dose 20 mL vial contains 400 mg daratumumab, glacial acetic acid (3.7 mg), mannitol (510 mg), polysorbate 20 (8 mg), sodium acetate trihydrate (59.3 mg), sodium chloride (70.1 mg), and water for injection.

Each DARZALEX single-dose 5 mL vial contains 100 mg daratumumab, glacial acetic acid (0.9 mg), mannitol (127.5 mg), polysorbate 20 (2 mg), sodium acetate trihydrate (14.8 mg), sodium chloride (17.5 mg), and water for injection.

CD38 is a transmembrane glycoprotein (48 kDa) expressed on the surface of hematopoietic cells, including multiple myeloma and other cell types and tissues and has multiple functions, such as receptor mediated adhesion, signaling, and modulation of cyclase and hydrolase activity. Daratumumab is an IgG1κ human monoclonal antibody (mAb) that binds to CD38 and inhibits the growth of CD38 expressing tumor cells by inducing apoptosis directly through Fc mediated cross linking as well as by immune-mediated tumor cell lysis through complement dependent cytotoxicity (CDC), antibody dependent cell mediated cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). A subset of myeloid derived suppressor cells (CD38+MDSCs), regulatory T cells (CD38+T) and B cells (CD38+B) are decreased by daratumumab.

NK cells express CD38 and are susceptible to daratumumab mediated cell lysis. Decreases in absolute counts and percentages of total NK cells (CD16+CD56+) and activated (CD16+CD56) NK cells in peripheral whole blood and bone marrow were observed with DARZALEX treatment.

Cardiac Electrophysiology

DARZALEX as a large protein has a low likelihood of direct ion channel interactions. There is no evidence from non-clinical or clinical data to suggest that DARZALEX has the potential to delay ventricular repolarization.

Over the dose range from 1 to 24 mg/kg as monotherapy or 1 to 16 mg/kg of DARZALEX in combination with other treatments, increases in area under the concentration-time curve (AUC) were more than dose-proportional.

Following the recommended dose of 16 mg/kg when DARZALEX was administered as monotherapy or in combination therapy, the mean serum maximal concentration (C) value at the end of weekly dosing, was approximately 2.7 to 3-fold higher compared to the mean serum Cfollowing the first dose. The mean ± standard deviation (SD) trough serum concentration (C) at the end of weekly dosing was 573 ± 332 µg/mL when DARZALEX was administered as monotherapy and 502 ± 196 to 607 ± 231 µg/mL when DARZALEX was administered as combination therapy. When DARZALEX was administered as monotherapy, daratumumab steady state was achieved approximately 5 months into the every 4-week dosing period (by the 21infusion), and the mean ± SD ratio of Cat steady-state to Cafter the first dose was 1.6 ± 0.5.

Distribution

At the recommended dose of 16 mg/kg, the mean ± SD central volume of distribution was 4.7 ± 1.3 L when DARZALEX was administered as monotherapy and 4.4 ± 1.5 L when DARZALEX was administered as combination therapy.

Elimination

Daratumumab clearance decreased with increasing dose and with multiple dosing. At the recommended dose of 16 mg/kg of DARZALEX as monotherapy, the mean ± SD linear clearance was estimated to be 171.4 ± 95.3 mL/day. The mean ± SD estimated terminal half-life associated with linear clearance was 18 ± 9 days when DARZALEX administered as monotherapy and a mean of 22–23 days when DARZALEX was administered as combination therapy.

Specific Populations

The following population characteristics have no clinically meaningful effect on the pharmacokinetics of daratumumab in patients administered DARZALEX as monotherapy or as combination therapy: sex, age (31 to 93 years), mild [total bilirubin 1 to 1.5 times upper limit of normal (ULN) or aspartate aminotransaminase (AST)>ULN] and moderate (total bilirubin 1.5 to 3 times ULN and any AST) hepatic impairment, or renal impairment [Creatinine clearance (CLcr) 15 –89 mL/min]. The effect of severe (total bilirubin >3 times ULN and any AST) hepatic impairment is unknown. Increasing body weight increased the central volume of distribution and clearance of daratumumab, supporting the body weight-based dosing regimen.

Drug Interactions

Effect of Other Drugs on Daratumumab

The coadministration of lenalidomide, pomalidomide or bortezomib with DARZALEX did not affect the pharmacokinetics of daratumumab.

Effect of Daratumumab on Other Drugs

The coadministration of DARZALEX with bortezomib or pomalidomide did not affect the pharmacokinetics of bortezomib or pomalidomide.

No carcinogenicity or genotoxicity studies have been conducted with daratumumab. No animal studies have been performed to evaluate the potential effects of daratumumab on reproduction or development, or to determine potential effects on fertility in males or females.

Combination Treatment with Bortezomib, Melphalan and Prednisone (VMP) in Patients Ineligible for Autologous Stem Cell Transplant

ALCYONE (NCT02195479), an open-label, randomized, active-controlled Phase 3 study, compared treatment with DARZALEX 16 mg/kg in combination with bortezomib, melphalan and prednisone (D-VMP), to treatment with VMP in patients with newly diagnosed multiple myeloma. Bortezomib was administered by subcutaneous (SC) injection at a dose of 1.3 mg/mbody surface area twice weekly at Weeks 1, 2, 4 and 5 for the first 6-week cycle (Cycle 1; 8 doses), followed by once weekly administrations at Weeks 1, 2, 4 and 5 for eight more 6-week cycles (Cycles 2–9; 4 doses per cycle). Melphalan at 9 mg/m, and prednisone at 60 mg/mwere orally administered on Days 1 to 4 of the nine 6-week cycles (Cycles 1–9). DARZALEX treatment was continued until disease progression or unacceptable toxicity.

A total of 706 patients were randomized: 350 to the D-VMP arm and 356 to the VMP arm. The baseline demographic and disease characteristics were similar between the two treatment groups. The median age was 71 (range: 40–93) years, with 30% of the patients ≥75 years of age. The majority were white (85%), female (54%), 25% had an Eastern Cooperative Oncology Group (ECOG) performance score of 0, 50% had an ECOG performance score of 1 and 25% had an ECOG performance score of 2. Nineteen percent of patients had ISS Stage I, 42% had ISS Stage II and 38% had ISS Stage III disease. Efficacy was evaluated by progression free survival (PFS) based on International Myeloma Working Group (IMWG) criteria.

ALCYONE demonstrated an improvement in PFS in the D-VMP arm as compared to the VMP arm; the median PFS had not been reached in the D-VMP arm and was 18.1 months (95% CI:16.53, 19.91) in the VMP arm (hazard ratio [HR]=0.5; 95% CI: 0.38, 0.65; p<0.0001), representing 50% reduction in the risk of disease progression or death in patients treated with D-VMP.

Figure 1: Kaplan-Meier Curve of PFS in ALCYONE

Additional efficacy results from ALCYONE are presented in Table 15 below.

In responders, the median time to response was 0.79 months (range: 0.4 to 15.5 months) in the D-VMP group and 0.82 months (range: 0.7 to 12.6 months) in the VMP group. The median duration of response had not been reached in the D-VMP group and was 21.3 months (range: 0.5+, 23.7+) in the VMP group.

Table 15: Additional efficacy results from ALCYONE
D-VMP (n=350) VMP (n=356)
D-VMP = daratumumab-bortezomib-melphalan-prednisone; VMP = bortezomib-melphalan-prednisone; MRD = minimal residual disease; CI = confidence interval
Overall response (sCR+CR+VGPR+PR) n(%)Based on intent-to-treat population 318 (90.9%) 263 (73.9%)
  p-valuep-value from Cochran Mantel-Haenszel Chi-Squared test. <0.0001
  Stringent complete response (sCR) 63 (18.0%) 25 (7.0%)
  Complete response (CR) 86 (24.6%) 62 (17.4%)
  Very good partial response (VGPR) 100 (28.6%) 90 (25.3%)
  Partial response (PR) 69 (19.7%) 86 (24.2%)
MRD negativity rate, Based on threshold of 10-5 n(%) 78 (22.3%) 22 (6.2%)
  95% CI (%) (18.0, 27.0) (3.9, 9.2)
  p-valuep-value from Fisherʼs exact test. <0.0001
MRD negativity rate in patients with CR or better n(%) 74 (49.7%) 22 (25.3%)
  95% CI (%) (41.4, 58.0) (16.6, 35.7)

Combination Treatment with Lenalidomide and Dexamethasone

POLLUX (NCT02076009), an open-label, randomized, active-controlled Phase 3 trial, compared treatment with DARZALEX 16 mg/kg in combination with lenalidomide and low-dose dexamethasone (DRd) to treatment with lenalidomide and low-dose dexamethasone (Rd) in patients with multiple myeloma who had received at least one prior therapy. Lenalidomide (25 mg once daily orally on Days 1–21 of repeated 28-day [4-week] cycles) was given with low dose oral or intravenous dexamethasone 40 mg/week (or a reduced dose of 20 mg/week for patients >75 years or body mass index [BMI] <18.5). On DARZALEX infusion days, 20 mg of the dexamethasone dose was given as a pre-infusion medication and the remainder given the day after the infusion. For patients on a reduced dexamethasone dose, the entire 20 mg dose was given as a DARZALEX pre-infusion medication. Dose adjustments for lenalidomide and dexamethasone were applied according to manufacturer's prescribing information. Treatment was continued in both arms until disease progression or unacceptable toxicity.

A total of 569 patients were randomized; 286 to the DRd arm and 283 to the Rd arm. The baseline demographic and disease characteristics were similar between the DARZALEX and the control arm. The median patient age was 65 years (range 34 to 89 years), 11% were ≥75 years, 59% were male; 69% Caucasian, 18% Asian, and 3% African American. Patients had received a median of 1 prior line of therapy. Sixty-three percent (63%) of patients had received prior autologous stem cell transplantation (ASCT). The majority of patients (86%) received a prior PI, 55% of patients had received a prior immunomodulatory agent, including 18% of patients who had received prior lenalidomide; and 44% of patients had received both a prior PI and immunomodulatory agent. At baseline, 27% of patients were refractory to the last line of treatment. Eighteen percent (18%) of patients were refractory to a PI only, and 21% were refractory to bortezomib. Efficacy was evaluated by progression free survival (PFS) based on International Myeloma Working Group (IMWG) criteria.

POLLUX demonstrated an improvement in PFS in the DRd arm as compared to the Rd arm; the median PFS had not been reached in the DRd arm and was 18.4 months in the Rd arm (hazard ratio [HR]=0.37; 95% CI: 0.27, 0.52; p<0.0001), representing 63% reduction in the risk of disease progression or death in patients treated with DRd.

Figure 2: Kaplan-Meier Curve of PFS in POLLUX

Additional efficacy results from POLLUX are presented in Table 16 below.

In responders, the median time to response was 1 month (range: 0.9 to 13 months) in the DRd group and 1.1 months (range: 0.9 to 10 months) in the Rd group. The median duration of response had not been reached in the DRd group (range: 1+ to 19.8+ months) and was 17.4 months (range: 1.4 to 18.5+ months) in the Rd group.

With a median follow-up of 13.5 months, 75 deaths were observed; 30 in the DRd group and 45 in the Rd group.

Table 16: Additional efficacy results from POLLUXBased on Intent-to-treat population
DRd (n=286) Rd (n=283)
DRd = daratumumab- lenalidomide-dexamethasone; Rd = lenalidomide-dexamethasone
Overall response (sCR+CR+VGPR+PR) 261 (91.3%) 211 (74.6%)
  p-valuep-value from Cochran Mantel-Haenszel Chi-Squared test. <0.0001
  Stringent complete response (sCR) 51 (17.8%) 20 (7.1%)
  Complete response (CR) 70 (24.5%) 33 (11.7%)
  Very good partial response (VGPR) 92 (32.2%) 69 (24.4%)
  Partial response (PR) 48 (16.8%) 89 (31.4%)

Combination Treatment with Bortezomib and Dexamethasone

CASTOR (NCT02136134), an open-label, randomized, active-controlled Phase 3 trial, compared treatment with DARZALEX 16 mg/kg in combination with bortezomib and dexamethasone (DVd), to treatment with bortezomib and dexamethasone (Vd) in patients with multiple myeloma who had received at least one prior therapy. Bortezomib was administered by SC injection or IV infusion at a dose of 1.3 mg/mbody surface area twice weekly for two weeks (Days 1, 4, 8, and 11) of repeated 21 day (3-week) treatment cycles, for a total of 8 cycles. Dexamethasone was administered orally at a dose of 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each of the 8 bortezomib cycles (80 mg/week for two out of three weeks of the bortezomib cycle) or a reduced dose of 20 mg/week for patients >75 years, BMI <18.5, poorly controlled diabetes mellitus or prior intolerance to steroid therapy. On the days of DARZALEX infusion, 20 mg of the dexamethasone dose was administered as a pre-infusion medication. For patients on a reduced dexamethasone dose, the entire 20 mg dose was given as a DARZALEX pre-infusion medication. Bortezomib and dexamethasone were given for 8 three-week cycles in both treatment arms; whereas DARZALEX was given until disease progression. However, dexamethasone 20 mg was continued as a DARZALEX pre-infusion medication in the DVd arm. Dose adjustments for bortezomib and dexamethasone were applied according to manufacturer's prescribing information.

A total of 498 patients were randomized; 251 to the DVd arm and 247 to the Vd arm. The baseline demographic and disease characteristics were similar between the DARZALEX and the control arm. The median patient age was 64 years (range 30 to 88 years); 12% were ≥75 years, 57% were male; 87% Caucasian, 5% Asian and 4% African American. Patients had received a median of 2 prior lines of therapy and 61% of patients had received prior autologous stem cell transplantation (ASCT). Sixty-nine percent (69%) of patients had received a prior PI (66% received bortezomib) and 76% of patients received an immunomodulatory agent (42% received lenalidomide). At baseline, 32% of patients were refractory to the last line of treatment and the proportions of patients refractory to any specific prior therapy were in general well balanced between the treatment groups. Thirty-three percent (33%) of patients were refractory to an immunomodulatory agent only, with 24% patients in the DVd arm and 33% of patients in the Vd arm respectively refractory to lenalidomide. Efficacy was evaluated by progression free survival (PFS) based on International Myeloma Working Group (IMWG) criteria.

CASTOR demonstrated an improvement in PFS in the DVd arm as compared to the Vd arm; the median PFS had not been reached in the DVd arm and was 7.2 months in the Vd arm (HR [95% CI]: 0.39 [0.28, 0.53]; p-value < 0.0001), representing a 61% reduction in the risk of disease progression or death for patients treated with DVd versus Vd.

Figure 3: Kaplan-Meier Curve of PFS in CASTOR

Additional efficacy results from CASTOR are presented in Table 17 below.

In responders, the median time to response was 0.8 months (range: 0.7 to 4 months) in the DVd group and 1.5 months (range: 0.7 to 5 months) in the Vd group. The median duration of response had not been reached in the DVd group (range: 1.4+ to 14.1+ months) and was 7.9 months (1.4+ to 12+ months) in the Vd group.

With a median follow-up of 7.4 months, 65 deaths were observed; 29 in the DVd group and 36 in the Vd group were observed.

Table 17: Additional efficacy results from CASTORBased on Intent-to-treat population
DVd (n=251) Vd (n=247)
DVd = daratumumab- bortezomib-dexamethasone; Vd = bortezomib-dexamethasone
Overall response (sCR+CR+VGPR+PR) 199 (79.3%) 148 (59.9%)
  P-valuep-value from Cochran Mantel-Haenszel Chi-Squared test. <0.0001
  Stringent complete response (sCR) 11 (4.4%) 5 (2.0%)
  Complete response (CR) 35 (13.9%) 16 (6.5%)
  Very good partial response (VGPR) 96 (38.2%) 47 (19.0%)
  Partial response (PR) 57 (22.7%) 80 (32.4%)

Combination Treatment with Pomalidomide and Dexamethasone

EQUULEUS (NCT01998971) was an open-label trial in which 103 patients with multiple myeloma who had received a prior PI and an immunomodulatory agent, received 16 mg/kg DARZALEX in combination with pomalidomide and low-dose dexamethasone until disease progression. Pomalidomide (4 mg once daily orally on Days 1–21 of repeated 28-day [4-week] cycles) was given with low dose oral or intravenous dexamethasone 40 mg/ week (reduced dose of 20 mg/week for patients >75 years or body mass index [BMI] <18.5). On DARZALEX infusion days, 20 mg of the dexamethasone dose was given as a pre-infusion medication and the remainder given the day after the infusion. For patients on a reduced dexamethasone dose, the entire 20 mg dose was given as a DARZALEX pre-infusion medication.

The median patient age was 64 years (range: 35 to 86 years) with 8% of patients ≥75 years of age. Patients in the study had received a median of 4 prior lines of therapy. Seventy-four percent (74%) of patients had received prior ASCT. Ninety-eight percent (98%) of patients received prior bortezomib treatment, and 33% of patients received prior carfilzomib. All patients received prior lenalidomide treatment, with 98% of patients previously treated with the combination of bortezomib and lenalidomide. Eighty nine percent (89%) of patients were refractory to lenalidomide and 71% refractory to bortezomib; 64% of patients were refractory to bortezomib and lenalidomide.

Efficacy results were based on overall response rate as determined by Independent Review Committee using IMWG criteria (see Table 18).

The median time to response was 1 month (range: 0.9 to 2.8 months). The median duration of response was 13.6 months (range: 0.9+ to 14.6+ months).

Table 18: Efficacy results for EQUULEUS
N=103
ORR = sCR+CR+VGPR+PR
CI=Confidence Interval
Overall response rate (ORR)
95% CI (%)
61 (59.2%)
(49.1, 68.8)
  Stringent complete response (sCR) 8 (7.8%)
  Complete response (CR) 6 (5.8%)
  Very good partial response (VGPR) 29 (28.2%)
  Partial response (PR) 18 (17.5%)

Monotherapy

SIRIUS (NCT01985126), was an open-label trial evaluating DARZALEX monotherapy in patients with relapsed or refractory multiple myeloma who had received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or who were double-refractory to a proteasome inhibitor and an immunomodulatory agent. In 106 patients, DARZALEX 16 mg/kg was administered with pre- and post-infusion medication. Treatment continued until unacceptable toxicity or disease progression.

The median patient age was 63.5 years (range: 31 to 84 years), 49% were male and 79% were Caucasian. Patients had received a median of 5 prior lines of therapy. Eighty percent of patients had received prior autologous stem cell transplantation (ASCT). Prior therapies included bortezomib (99%), lenalidomide (99%), pomalidomide (63%) and carfilzomib (50%). At baseline, 97% of patients were refractory to the last line of treatment, 95% were refractory to both, a proteasome inhibitor (PI) and immunomodulatory agent, and 77% were refractory to alkylating agents.

Efficacy results were based on overall response rate as determined by the Independent Review Committee assessment using IMWG criteria (see Table 19).

The median time to response was 1 month (range: 0.9 to 5.6 months). The median duration of response was 7.4 months (range: 1.2 to 13.1+ months).

Study GEN501 (NCT00574288) was an open-label dose escalation trial evaluating DARZALEX monotherapy in patients with relapsed or refractory multiple myeloma who had received at least 2 different cytoreductive therapies. In 42 patients, DARZALEX 16 mg/kg was administered with pre- and post-infusion medication. Treatment continued until unacceptable toxicity or disease progression.

The median patient age was 64 years (range: 44 to 76 years), 64% were male and 76% were Caucasian. Patients in the study had received a median of 4 prior lines of therapy. Seventy-four percent of patients had received prior ASCT. Prior therapies included bortezomib (100%), lenalidomide (95%), pomalidomide (36%) and carfilzomib (19%). At baseline, 76% of patients were refractory to the last line of treatment, 64% of patients were refractory to both, a PI and an immunomodulatory agent, and 60% of patients were refractory to alkylating agents.

Overall response rate was 36% (95% CI: 21.6, 52.0%) with 1 CR and 3 VGPR. The median time to response was 1 month (range: 0.5 to 3.2 months). The median duration of response was not estimable (range: 2.2 to 13.1+ months).

Table 19: Efficacy results for SIRIUS
N=106
ORR = sCR+CR+VGPR+PR
CI = confidence interval
Overall response rate (ORR)
95% CI (%)
31 (29.2%)
(20.8, 38.9)
  Stringent complete response (sCR) 3 (2.8%)
  Complete response (CR) 0
  Very good partial response (VGPR) 10 (9.4%)
  Partial response (PR) 18 (17.0%)

DARZALEX is a colorless to pale yellow, preservative-free solution for intravenous infusion supplied as:

NDC 57894-502-05 contains one 100 mg/5 mL single-dose vial

NDC 57894-502-20 contains one 400 mg/20 mL single-dose vial

Store in a refrigerator at 2°C to 8°C (36°F to 46°F).

Do not freeze or shake. Protect from light. This product contains no preservative.

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Infusion Reactions

Advise patients to seek immediate medical attention for any of the following signs and symptoms of infusion reactions:

Neutropenia

Thrombocytopenia

Interference with Laboratory Tests

Advise patients to inform healthcare providers including blood transfusion centers/personnel that they are taking DARZALEX, in the event of a planned transfusion [see Warnings and Precautions (5.2) and Drug Interactions (7.1)].

Advise patients that DARZALEX can affect the results of some tests used to determine complete response in some patients and additional tests may be needed to evaluate response [see Warnings and Precautions (5.5) and Drug Interactions (7.1)].

Manufactured by:Janssen Biotech, Inc.Horsham, PA 19044U.S. License Number 1864

© 2015 Janssen Pharmaceutical Companies

PATIENT INFORMATION
DARZALEX® (Dar'-zah-lex)
(daratumumab)
injection, for intravenous use
This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: June/2018
What is DARZALEX?
DARZALEX is a prescription medicine used to treat multiple myeloma: in combination with the medicines bortezomib, melphalan and prednisone, in people with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant). in combination with the medicines lenalidomide and dexamethasone, or bortezomib and dexamethasone, in people who have received at least one prior medicine to treat multiple myeloma. in combination with the medicines pomalidomide and dexamethasone in people who have received at least two prior medicines to treat multiple myeloma, including lenalidomide and a proteasome inhibitor. alone in people who have received at least three prior medicines to treat multiple myeloma, including a proteasome inhibitor and an immunomodulatory agent, or did not respond to a proteasome inhibitor and an immunomodulatory agent. It is not known if DARZALEX is safe and effective in children.
Do not receive DARZALEX if you have a history of a severe allergic reaction to daratumumab or any of the ingredients in DARZALEX. See the end of this leaflet for a complete list of ingredients in DARZALEX.
Before you receive DARZALEX, tell your healthcare provider about all of your medical conditions, including if you: have a history of breathing problems have had shingles (herpes zoster) are pregnant or plan to become pregnant. DARZALEX may harm your unborn baby. Females who are able to become pregnant should use an effective method of birth control during treatment and for at least 3 months after your final dose of DARZALEX. Talk to your healthcare provider about birth control methods that you can use during this time. are breastfeeding or plan to breastfeed. It is not known if DARZALEX passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How will I receive DARZALEX? DARZALEX may be given alone or together with other medicines used to treat multiple myeloma. DARZALEX will be given to you by your healthcare provider by intravenous (IV) infusion into your vein. Your healthcare provider will decide the time between doses as well as how many treatments you will receive. Your healthcare provider will give you medicines before each dose of DARZALEX and after each dose of DARZALEX to help reduce the risk of infusion reactions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.
What are the possible side effects of DARZALEX?
DARZALEX may cause serious reactions, including: Infusion reactions. Infusion reactions are common with DARZALEX and can be severe or serious. Your healthcare provider may temporarily stop your infusion or completely stop treatment with DARZALEX if you have infusion reactions. Get medical help right away if you get any of the following symptoms:
shortness of breath or trouble breathing dizziness or lightheadedness (hypotension) cough wheezing throat tightness runny or stuffy nose headache itching nausea vomiting chills fever
Changes in blood tests. DARZALEX can affect the results of blood tests to match your blood type. These changes can last for up to 6 months after your final dose of DARZALEX. Your healthcare provider will do blood tests to match your blood type before you start treatment with DARZALEX. Tell all of your healthcare providers that you are being treated with DARZALEX before receiving blood transfusions. Decreases in blood cell counts. DARZALEX can decrease white blood cell counts which help fight infections and blood cells called platelets which help to clot blood. Your healthcare provider will check your blood cell counts during treatment with DARZALEX. Tell your healthcare provider if you develop fever or have signs of bruising or bleeding. The most common side effects of DARZALEX include:
tiredness nausea diarrhea shortness of breath trouble sleeping fever cough muscle spasms back pain joint pain vomiting cold-like symptoms (upper respiratory infection) nerve damage causing tingling, numbness or pain swollen hands ankles or feet constipation chills dizziness
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of DARZALEX. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of DARZALEX
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your healthcare provider or pharmacist for information about DARZALEX that is written for health professionals.
What are the ingredients in DARZALEX?
Active ingredient: daratumumab
Inactive ingredients: glacial acetic acid, mannitol, polysorbate 20, sodium acetate trihydrate, sodium chloride, and water for injection
Manufactured by: Janssen Biotech, Inc., Horsham, PA 19044 U.S. License Number 1864
For more information, call 1-800-526-7736 or go to www.DARZALEX.com.

NDC 57894-502-05Rx only

DARZALEX (daratumumab)Injection100 mg/5 mL(20 mg/mL)

For Intravenous Infusion Only Dilute Before UseSingle-Dose Only. Discard UnusedPortion

janssen

Manufacturer

Janssen Biotech, Inc.

Active Ingredients

Source

Drugs and Medications [0 Results]

None

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma

PREDATOR is a study investigating a role of preemptive daratumumab therapy for preclinical relapse or progression of multiple myeloma (MM).

MUK Nine b: OPTIMUM Treatment Protocol

To determine whether a combination of four novel agents bortezomib(Velcade), lenalidomide (Revlimid), Daratumumab (Darzalex) & dexamethasone in combination with low-dose cyclophosphamide i...

A Pilot Presurgical Study of Daratumumab in Men With High-Risk Localized Prostate Cancer

The goal of this clinical research study is to learn about the safety and tolerability of giving Darzalex (daratumumab) to patients who have prostate cancer before having an already-schedu...

A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent

The purpose of this study is to demonstrate the safety profile of daratumumab in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory mul...

PubMed Articles [0 Results]

None

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record